- Home
- COLL vs TRIN Comparison
COLL vs TRIN Comparison
Compare COLL & TRIN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- COLL
- TRIN
- Stock Information
- Founded
- COLL 2002
- TRIN 2007
- Country
- COLL United States
- TRIN United States
- Employees
- COLL 357
- TRIN N/A
- Industry
- COLL Biotechnology: Pharmaceutical Preparations
- TRIN Finance/Investors Services
- Sector
- COLL Health Care
- TRIN Finance
- Exchange
- COLL Nasdaq
- TRIN Nasdaq
- Market Cap
- COLL 1.1B
- TRIN 1.2B
- IPO Year
- COLL 2015
- TRIN 2021
- Fundamental
- Price
- COLL $34.62
- TRIN $15.11
- Analyst Decision
- COLL Strong Buy
- TRIN Buy
- Analyst Count
- COLL 4
- TRIN 4
- Target Price
- COLL $44.25
- TRIN $15.63
- AVG Volume (30 Days)
- COLL 319.8K
- TRIN 783.8K
- Earning Date
- COLL 11-06-2025
- TRIN 11-05-2025
- Dividend Yield
- COLL N/A
- TRIN 13.55%
- EPS Growth
- COLL N/A
- TRIN 32.58
- EPS
- COLL 1.06
- TRIN 2.25
- Revenue
- COLL $707,007,000.00
- TRIN $254,887,000.00
- Revenue This Year
- COLL $21.29
- TRIN $27.19
- Revenue Next Year
- COLL $3.36
- TRIN $8.97
- P/E Ratio
- COLL $32.88
- TRIN $6.70
- Revenue Growth
- COLL 22.61
- TRIN 33.44
- 52 Week Low
- COLL $23.23
- TRIN $12.50
- 52 Week High
- COLL $39.95
- TRIN $16.82
- Technical
- Relative Strength Index (RSI)
- COLL 49.72
- TRIN 48.93
- Support Level
- COLL $34.46
- TRIN $15.03
- Resistance Level
- COLL $35.90
- TRIN $15.38
- Average True Range (ATR)
- COLL 0.97
- TRIN 0.26
- MACD
- COLL 0.19
- TRIN 0.07
- Stochastic Oscillator
- COLL 69.18
- TRIN 69.32
About COLL Collegium Pharmaceutical Inc.
Collegium Pharmaceutical Inc is a specialty pharmaceutical company. The company is engaged in developing and planning to commercialize abuse-deterrent products that incorporate its patented DETERx platform technology for the treatment of chronic pain and other diseases. The DETERx platform technology is designed to maintain the extended-release and safety profiles of abused drugs in the face of various methods including chewing, crushing, and dissolving. Its product portfolio includes Jornay, Xtampza ER, which is an abuse-deterrent, extended-release, oral formulation of oxycodone; and Nucynta Products, which are extended-release and immediate-release formulations of tapentadol; Belbuca, and Symproic.
About TRIN Trinity Capital Inc.
Trinity Capital Inc is a closed-end, non-diversified management investment company. The company is engaged in providing debt, including loans and equipment financings, to growth-stage companies, including venture-backed companies and companies with institutional equity investors. Its equipment financings involve loans for general or specific use, including acquiring equipment, secured by the equipment or other assets of the portfolio company.